Login to Your Account



Another 'weight' for Contrave; Orexigen falls on FDA delay

By Jennifer Boggs
Managing Editor

Wednesday, June 11, 2014
us_resized.jpg

Already trailing approvals of obesity drugs Belviq (lorcaserin) and Qsymia (phentermine/topiramate) by two years, Orexigen Therapeutics Inc.'s Contrave (naltrexone/bupropion) is facing another delay at the hands of the FDA, which pushed back the PDUFA date by three months to Sept. 11.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription